covid-19 – Retraction Watch

Exclusive: Reviewer recommended against publishing paper on DNA in COVID vaccines

Rolf Marschalek was on vacation when he saw a new paper had been published in the journal Autoimmunity. Marschalek, a biochemist at Goethe University Frankfurt in Germany, was “very upset,” he told Retraction Watch – because he’d peer-reviewed the manuscript and had recommended against publication.

The authors of the paper claimed to find DNA in mRNA-based COVID-19 vaccines above regulators’ suggested amounts. The article appeared online September 6, and within weeks the publisher began an investigation into concerns about its content, as we reported previously.

In Marschalek’s initial review, which he provided to us, he detailed how Qubit fluorometry, one of the methods the authors used to measure the amount of DNA in the vaccine vials, was “not suited” for use when samples contain much higher amounts of RNA than DNA, as is the case with mRNA-based COVID-19 vaccines. He cited a paper he and colleagues had written about methods of quantifying amounts of RNA and DNA in mRNA vaccine vials, including Qubit.

Lancet journal retracts COVID-19 metformin paper nearly 2 years after authors request correction

A paper on a clinical trial of metformin for the treatment of COVID-19 has been retracted nearly two years after the authors flagged data issues that resulted in an expression of concern.

The results of the Brazil-based TOGETHER trial, published in December 2021 in The Lancet Regional Health–Americas, found metformin was no better than placebo at improving health outcomes in people with COVID-19. The study has been cited 45 times, 25 of which came after the expression of concern was published, according to Clarivate’s Web of Science.

Early observational studies in people with COVID-19 found positive effects of metformin, an oral medication most often used for type 2 diabetes, including reduced disease severity and mortality rates. But clinical trials, including the now-retracted study and a more recent randomized trial, found no differences in time to recovery or disease severity between patients who got metformin and those who received placebo.

Authors defend retracted paper on vitamin D and COVID-19 called ‘deeply bizarre’ by critic

PLOS One has retracted a paper linking vitamin D levels and COVID-19 morbidity three years after a critic flagged the data in the study as “deeply bizarre.” The authors objected to the retraction, with one calling it “outrageous” and pointing to flaws in the published notice.

The article, which appeared in February 2022, claimed people with low levels of vitamin D were at increased risk for severe COVID-19 and were more likely to die of the disease than other patients. It has been cited 65 times, according to Clarivate’s Web of Science.

The paper had a “huge, immediate impact,” said Gideon Meyerowitz-Katz, a senior research fellow from the University of Wollongong in Australia, citing the fact that the paper had been viewed over 1 million times within six weeks of being published. The article joins others, many also flagged by Meyerowitz-Katz, purporting to find links between vitamin D intake and COVID-19 severity that have been retracted or removed.

Exclusive: Publisher investigating DNA contamination paper that authors say CDC vaccine committee will consider

The publisher Taylor & Francis is investigating concerns raised on PubPeer about a paper claiming to find DNA contamination in COVID-19 vaccines beyond regulators’ recommended amounts.

The move comes as the U.S. body tasked with making recommendations for vaccine use is scheduled to consider the safety of COVID-19 shots, and two of the study’s authors say their findings will be discussed.

The paper at issue was published September 6 in the journal Autoimmunity, a Taylor & Francis title. Scientific sleuth Kevin Patrick soon posted concerns on PubPeer, which he forwarded to the ethics department of the publisher.

Microbiome company CEO who linked COVID vaccine to bacterial decline now has four retractions

A gastroenterologist and microbiome researcher who has promoted hydroxychloroquine and ivermectin as COVID treatments has lost a paper after a sleuth reported differences between the article and the registered protocol of the clinical trial it purported to describe.

The retracted article, on detecting SARS-CoV-2 in fecal samples, was published in Gut Pathogens in January 2021. It marks the fourth retraction for study coauthor Sabine Hazan.

Hazan is founder and CEO of ProgenaBiome, a laboratory in Ventura, Calif., advertising clinical trials exploring the role of the gut microbiome in conditions including autism and Alzheimer’s disease, as well as COVID. She is also CEO of Ventura Clinical Trials, which lists dozens of pharmaceutical and biotech companies among its clients.

Slovak science academy ‘strictly condemns’ government official’s paper on mRNA vaccines

Slovakia’s national science academy has issued a strong critique of a paper on mRNA vaccines coauthored by a member of the country’s parliament. The group called the work “insufficiently detailed” and “lacking controls,” with data that “may be misleading” and conclusions “not supported by sufficiently robust data.”

Peter Kotlár, the paper’s second author, is an orthopedist and represents the far-right Slovak National Party. He is also the commissioner for a review of resource management during the COVID-19 pandemic for the government of populist prime minister Robert Fico, himself known for questioning the science around COVID-19.

The paper appeared May 13 in the Journal of Angiology and Vascular Surgery, published by Herald Scholarly Open Access. “The journal in which the study of Peter Kotlár was published, is not evidenced in databases Web Of Science and Scopus,” a spokesperson for the Slovak Academy of Sciences, Monika Tináková, told us. The issues with the paper reflect “the fact that the journal in which it was published is classified as a so-called predatory journal,” the statement, issued last month, reads.

Why has it taken more than a year to correct a COVID-19 paper?

A correction to a clinical trial on a potential treatment for COVID-19 has taken more than a year — and counting — to get published. In the meantime, the article remains marked with an expression of concern that appeared in February 2024.

The Lancet Regional Health–Americas published the study, a randomized clinical trial of the effect of metformin on hospitalization rates among COVID-19 patients, in December 2021. It has been cited 36 times, according to Clarivate’s Web of Science, 12 of those since the publication of the expression of concern.

In December 2023, the authors “identified small errors in the statistical analysis primary outcome,” corresponding author Edward Mills, a health research methods professor at McMaster University, in Hamilton, Ontario, told Retraction Watch. “We immediately re-ran the analysis and submitted as an erratum,” he said.

EcoHealth Alliance retracts and replaces paper on potential origin of COVID-19 in bats

The authors of an influential but controversial 2020 paper on the activity of bat coronaviruses in China which proposed the animals as a “likely origin” for the virus that causes COVID-19 have retracted their work and republished a revised version of the analysis. They say their results and conclusions did not change.

The paper, “Origin and cross-species transmission of bat coronaviruses in China,” appeared Aug. 25, 2020, in Nature Communications. It has been cited 154 times, according to Clarivate’s Web of Science, and by at least two international policy documents.

The authors are affiliated with the Wuhan Institute of Virology and the New York City-based nonprofit organization EcoHealth Alliance, which has come under intense scrutiny by members of the U.S. Congress and others. The U.S. government in May suspended funding for EcoHealth amid concerns the COVID-19 pandemic virus may have developed from research on which the nonprofit and Wuhan lab collaborated – a so-called “lab leak.” EcoHealth has denied the pandemic virus could have emerged from its work.

How an article estimating deaths from hydroxychloroquine use came to be retracted

An article estimating how many people might have died during the first wave of the COVID-19 pandemic due to the off-label use of hydroxychloroquine in hospitals was retracted in August after advocates for the drug launched a campaign criticizing the study.

French media have reported criticism of the retraction as inappropriate, and speculation the journal caved to pressure from hydroxychloroquine advocates.

In a statement to Retraction Watch, the journal stood by its decision to retract the article due to “some clear fatal flaws” identified in letters to the editor, which it said it declined to publish due to their tone it deemed “not suitable for publication in a scientific journal.”

‘Coding’ errors prompt retraction of paper on long COVID in kids

JAMA Pediatrics has retracted a controversial 2023 paper on the incidence of long COVID in children after the authors discovered a raft of “coding” errors in their analysis that greatly underestimated the risk of the condition.

The article – a research letter titled “Post–COVID-19 Condition in Children” – was written by a group of researchers in Canada led by Lyndsey Hahn, of the University of Alberta, in Edmonton. It has been cited eight times, according to Clarivate Analytics’ Web of Science, and garnered significant attention on mainstream and social media sites, including by critics who said the authors fatally botched the definition of long COVID.

According to the authors, the incidence of long covid in kids was “strikingly low”, occurring in just 0.4% of young patients. Symptoms of infection in kids typically resolve within two weeks, they added.

But those reassuring findings hinged on several errors in the analysis that made the incidence of long COVID in children look less than a third of what the researchers should have reported.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: